Cite
Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021;29(7):2366-2377doi: 10.1016/j.ymthe.2021.03.020.
Younis, B. M., Osman, M., Khalil, E. A. G., Santoro, F., Furini, S., Wiggins, R., Keding, A., Carraro, M., Musa, A. E. A., Abdarahaman, M. A. A., Mandefield, L., Bland, M., Aebischer, T., Gabe, R., Layton, A. M., Lacey, C. J. N., Kaye, P. M., & Musa, A. M. (2021). Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Molecular therapy : the journal of the American Society of Gene Therapy, 29(7), 2366-2377. https://doi.org/10.1016/j.ymthe.2021.03.020
Younis, Brima M, et al. "Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan." Molecular therapy : the journal of the American Society of Gene Therapy vol. 29,7 (2021): 2366-2377. doi: https://doi.org/10.1016/j.ymthe.2021.03.020
Younis BM, Osman M, Khalil EAG, Santoro F, Furini S, Wiggins R, Keding A, Carraro M, Musa AEA, Abdarahaman MAA, Mandefield L, Bland M, Aebischer T, Gabe R, Layton AM, Lacey CJN, Kaye PM, Musa AM. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021 Jul 07;29(7):2366-2377. doi: 10.1016/j.ymthe.2021.03.020. Epub 2021 Mar 27. PMID: 33781913; PMCID: PMC8261165.
Copy
Download .nbib